Rachel Warren

Now, contrast that to a business like TJX Companies.

Obviously, the business models of these companies are different, but still, there could not be more variance.

Absolutely.

Where you've got Target forecasting a week holiday season, sales are down.

The CEO of TGX Company said, the holiday shopping season is off to a strong start for us.

They said, our availability of merchandise is outstanding.

We're really excited about the deals that we're seeing.

They're expecting comparable sales to rise between 2% and 3%.

They even elevated their upcoming expectations after their better-than-expected Q3 results.

A really strong quarter for TGX companies, a very weak quarter for Target.

I think what we're seeing is, maybe consumer weaknesses persist, but how that plays out to different companies is going to be on a very much case-by-case basis.

This is an area that Pfizer has wanted to expand into for a while now.

You might remember at one point, they actually had their own GLP-1 candidate.

They had to discontinue that back in April of this year.

There had been a bidding war that essentially erupted between Pfizer and Novonordisk for Metzera.

That started back after Pfizer's initial offer in September.

Pfizer ultimately won the bid.

They had a sweetened offer of up to $10 billion.

And this acquisition could really position Pfizer in the long run in the highly competitive and obviously growing obesity treatment market where they've previously struggled with their own development.

So, Metzera has a pipeline of drug candidates for metabolic diseases that target different gut hormones that offer some really key advantages in efficacy and tolerance.